In these cells, B-RAF inhibitors cause compensatory upregulation of C-RAF, which leads to paradoxical activation of the MAP kinase pathway via downstream kinases MEK and ERK; this was originally shown in human anaplastic carcinoma cells (21). The gene discussed is RAF1; the disease is undifferentiated carcinoma.